SG11202007503WA - A process for enterovirus purification and inactivation and vaccine compositions obtained thereof - Google Patents

A process for enterovirus purification and inactivation and vaccine compositions obtained thereof

Info

Publication number
SG11202007503WA
SG11202007503WA SG11202007503WA SG11202007503WA SG11202007503WA SG 11202007503W A SG11202007503W A SG 11202007503WA SG 11202007503W A SG11202007503W A SG 11202007503WA SG 11202007503W A SG11202007503W A SG 11202007503WA SG 11202007503W A SG11202007503W A SG 11202007503WA
Authority
SG
Singapore
Prior art keywords
enterovirus
inactivation
purification
vaccine compositions
compositions obtained
Prior art date
Application number
SG11202007503WA
Inventor
Krishna Murthy Ella
Vijaya Kumar Daram
Original Assignee
Bharat Biotech Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bharat Biotech Int Ltd filed Critical Bharat Biotech Int Ltd
Publication of SG11202007503WA publication Critical patent/SG11202007503WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32651—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32651—Methods of production or purification of viral material
    • C12N2770/32652—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32661—Methods of inactivation or attenuation
    • C12N2770/32663—Methods of inactivation or attenuation by chemical treatment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
SG11202007503WA 2018-02-07 2019-02-06 A process for enterovirus purification and inactivation and vaccine compositions obtained thereof SG11202007503WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201841004703 2018-02-07
PCT/IN2019/050095 WO2019155492A1 (en) 2018-02-07 2019-02-06 A process for enterovirus purification and inactivation and vaccine compositions obtained thereof

Publications (1)

Publication Number Publication Date
SG11202007503WA true SG11202007503WA (en) 2020-09-29

Family

ID=67548350

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202007503WA SG11202007503WA (en) 2018-02-07 2019-02-06 A process for enterovirus purification and inactivation and vaccine compositions obtained thereof

Country Status (5)

Country Link
US (1) US11911457B2 (en)
EP (1) EP3749757A4 (en)
SG (1) SG11202007503WA (en)
WO (1) WO2019155492A1 (en)
ZA (1) ZA202005510B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202106394PA (en) * 2018-12-29 2021-07-29 Bharat Biotech Int Ltd Adaptation of enterovirus to vero cells and vaccine formulations thereof
WO2022070210A1 (en) * 2020-09-29 2022-04-07 Bharat Biotech International Limited Stable formulations of low abundance enteroviruses vaccines and process of manufacture thereof
WO2022254459A1 (en) * 2021-05-31 2022-12-08 Bharat Biotech International Limited Adjuvanted inactivated recombinant rabies virus vectored coronavirus vaccine formulations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4525349A (en) 1981-12-29 1985-06-25 Societe Anonyme Dite: Institut Merueux Process for the large-scale production of a vaccine against poliomyelitis and the resulting vaccine
US6951752B2 (en) 2001-12-10 2005-10-04 Bexter Healthcare S.A. Method for large scale production of virus antigen
US20080193478A1 (en) * 2004-08-27 2008-08-14 Rajesh Jain Inactivated Poliomyelitis Vaccine Derived From Sabin Strain Of Polio Virus
SG177655A1 (en) 2009-07-16 2012-02-28 Crucell Holland Bv Production of polio virus at high titers for vaccine production
BR112013005049A2 (en) * 2010-09-02 2016-05-31 Sanofi Pasteur stabilizer for the preparation of an injectable dry polio vaccine composition
EP2699266B1 (en) * 2011-04-21 2019-06-12 Trustees Of Tufts College Compositions and methods for stabilization of active agents
WO2012171026A2 (en) 2011-06-10 2012-12-13 Biovest International, Inc. Methods for high yield virus production
PL3010537T3 (en) * 2013-06-17 2019-03-29 De Staat Der Nederlanden, Vert. Door De Minister Van Vws, Ministerie Van Volksgezondheid, Welzijn En Sport Methods for the prevention of aggregation of viral components
US10294460B2 (en) * 2014-07-24 2019-05-21 Janssen Vaccines & Prevention B.V. Process for the purification of poliovirus from cell cultures
KR102219638B1 (en) 2014-10-07 2021-02-23 세럼 인스티튜트 오브 인디아 프라이비트 리미티드 Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof
JP2019532624A (en) * 2016-09-01 2019-11-14 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. Method for producing virus for vaccine production

Also Published As

Publication number Publication date
US11911457B2 (en) 2024-02-27
WO2019155492A1 (en) 2019-08-15
EP3749757A1 (en) 2020-12-16
EP3749757A4 (en) 2021-11-24
US20200376110A1 (en) 2020-12-03
ZA202005510B (en) 2021-08-25

Similar Documents

Publication Publication Date Title
HRP20190352T1 (en) Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
HK1251554A1 (en) Novel substituted aminothiazolopyrimidinedione for the treatment and prophylaxis of virus infection
HK1248711A1 (en) Novel substituted aminothiazolopyrimidinedione for the treatment and prophylaxis of virus infection
HK1223931A1 (en) Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
ZA202005510B (en) A process for enterovirus purification and inactivation and vaccine compositions obtained thereof
GB201814362D0 (en) Composition and process for preparing vaccine
IL282881A (en) Methods for treating hepatitis b infection
HK1250480A1 (en) Compositions and methods for the treatment of hbv infection
HRP20180639T1 (en) Isoindoline derivatives for use in the treatment of a viral infection
ZA201903110B (en) Air pollutant treatment process
HK1252343A1 (en) Compositions and methods for the treatment of viral infection
SG10202010814RA (en) Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof
GB201806736D0 (en) Method for virus purification
ZA202101026B (en) Methods and compositions for producing a virus
EP3197465A4 (en) Compositions and methods for treating a viral infection
ZA201604784B (en) Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection